Tag Archives: analysis

Quality From Canada

Inside Red Light Holland’s Plan to Bring Psilocybin Products to the Global Market

By Pam Chmiel
2 Comments

Red Light Holland (CSE: TRIP) has established its foundation in the Netherlands, where psilocybin truffles, the underground sclerotia of psilocybin mushrooms, are legally permitted for cultivation and sale. The above-ground mushroom is prohibited, but the truffle is treated differently under Dutch law, despite delivering the same psychoactive effects.

“It’s really the same thing, with the same effects,” says CEO Todd Shapiro, “but because it forms underground, it can be sold in compliance with Dutch law.”

From its cultivation facility, RLH distributes truffles through a wholesale partnership to over 150 wellness shops under its brands iMicrodose and Maka. “We like to think of them as wellness shops rather than smart shops, like they are referred to in Holland,” Shapiro explains, underscoring the company’s emphasis on education, QR-code-based information, and community engagement. While regulations prevent RLH from turning truffles into edibles such as gummies or chocolates, its vacuum-sealed, raw truffles have become a steady revenue stream. “They’re a bit walnut-y,” Shapiro notes, “but they sell well and people rarely complain.”

 

Canada: Positioning for a Regulated Future                                                           In Canada, RLH is preparing for the potential regulatory shift that could pave the way for the legalization of psilocybin products. The company has already developed psilocybin gummy formulations, but for now, it only sells them as functional mushroom products that don’t contain psilocybin. This approach not only helps build brand recognition, but it also keeps the company R&D-ready, allowing it to move quickly if Health Canada establishes a legal framework for psilocybin.

 

United States: Research Partnerships for Validation                                        South of the border, RLH has partnered with Irvine Labs, a DEA-registered laboratory in California. The lab is testing RLH’s truffles, imported from the Netherlands, to confirm potency, safety, and pharmacological value. The partnership is central to RLH’s long-term vision of formulating psilocybin capsules tailored to various needs, including microdosing, therapeutic use, and wellness.

Shapiro frames the multi-pronged approach as deliberate groundwork for the future. “The Netherlands gives us a legal, revenue-generating business today. Canada positions us for tomorrow. And in the U.S., we’re laying the foundation with science so that when the regulatory environment changes, we’ll be ready.”

 

Research & Consumer Insights                                                                                In addition to building commercial distribution, Red Light Holland is investing in research that could help shape future regulations. Through its iMicrodose app, the company collects voluntary, anonymized data from consumers in the Netherlands on how they are using psilocybin truffles, whether for trauma, pain management, recreation, or general wellness. Shapiro points to a substantial interest in using psilocybin to tame menopause symptoms from their data.

 

“We ask our consumers if they’d like to participate in the app and give us data on how they’re using it,” explains Shapiro.

 

The data was analyzed in collaboration with Drug Science UK under the leadership of renowned neuroscientist Professor David Nutt, one of the most respected voices in psychedelic research and policy. The published study confirmed that RLH’s data provided meaningful evidence of consumer benefit. “A lot of it is anecdotal research, which is key research,” says Shapiro. “It’s almost like its own Phase 1.”

The findings also carried a regulatory impact. RLH presented its consumer data to lawmakers in Oregon as they developed the state’s psilocybin program, contributing to the inclusion of microdosing language in the final bill. “This was a huge win for the company,” Shapiro says. “It adds credibility, validation, and shows how we can responsibly influence policy through science-backed data.”

For RLH, consumer research serves a dual purpose: it provides a self-regulatory framework for the safe distribution of products today, and it informs the company’s plans for future formulations as regulations evolve.

 

Standardization & Medical Pathways                                                                   Red Light Holland is also working behind the scenes to prepare psilocybin for the medical market. The company has partnered with labs in both Canada and the U.S. to analyze and standardize its products, laying the groundwork for future pharmaceutical-style formulations.

In Canada, RLH has collaborated with Seacrest Laboratories in Montreal, securing multiple permits for the import of psilocybin from Health Canada. These projects have produced certificates of analysis (COAs) to understand psilocybin content better and explore standardized dosing formats. “We’re learning about the standardization of our product,” says Shapiro, “whether that eventually becomes ground into powder form or an extract. The end goal is to move toward a consistent, pill-like product for microdosing.”

In the U.S., RLH works with Irvine Labs in California, a rare FDA-approved, DEA-compliant facility, to advance similar objectives. The partnership underscores RLH’s long-term ambition: validating its Dutch truffles as a source for medical-grade psilocybin products that could one day be distributed under compassionate care or special access programs.

“It’s a slow path,” Shapiro admits. “No one would normally start a business that they could only sell in about one percent of the world. But if you want to be an outlier versus an outlaw, you take the careful approach by generating sustainable revenue in Holland while advancing science and regulations in North America.”

 

Slow and Steady                                                                                                    While regulatory doors are starting to crack open in places like Germany, Australia, New Zealand, and the Czech Republic, RLH isn’t rushing in. Shapiro is careful to point out that the company has no interest in repeating the mistakes of many cannabis operators who built massive facilities before the market was ready, only to burn through cash and collapse in oversaturated conditions. Instead, RLH is pacing itself, positioning products, standardizing formulations, and preparing for the moment commercialization becomes viable.

“It’s frustrating for some investors who want instant results,” Shapiro admits, “but the reality is we can only sell in one percent of the world right now. We’d run out of money if we tried to scale too fast. Every move has to be deliberate.”

For RLH, the mission remains steady: take psilocybin from the underground to the mainstream. Until regulations evolve, the company is committed to cautious progress, ensuring it will be ready to deliver once legalization expands.

 

Market Readiness                                                                                                       To help normalize psilocybin, RLH has leveraged functional mushrooms with its Happy Caps grow kits and mushroom gummies to establish brand awareness. Happy Caps started as homegrow kits for lion’s mane, shiitake, and oyster mushrooms, products that ended up on the shelves of Costco and other major Canadian retailers. The idea is simple: just as Canada allowed adults to grow cannabis at home after legalization, psilocybin might one day follow a similar path. If that happens, RLH will already be positioned with both the distribution channels and consumer familiarity to shift from lion’s mane to psilocybin.

More recently, RLH launched mushroom gummies in Canada made with a lion’s mane and shiitake blend. These gummies carry a Health Canada–approved NPN number, which allows the company to make validated health claims, such as immune-boosting and antioxidant properties that most competitors cannot legally advertise. Shapiro says this not only sets RLH apart in the crowded functional mushroom category, but also provides a ready-made blueprint for psilocybin gummies once regulations allow. “It’s a much easier way to consume than chewing on a raw truffle,” he explains. In other words, today’s Happy Caps gummies are tomorrow’s psilocybin edibles.

In parallel, RLH is deepening its scientific foundation through a partnership with Irvine Labs. The company has already imported truffle samples for testing, focusing on potency, shelf-life stability, and consistency—critical steps in moving psilocybin from a naturally variable product to a standardized medicine. “If you’re microdosing for medical reasons, you want to be sure each dose delivers the same effect,” Shapiro explains.

That requires rigorous testing under pharmaceutical standards, much like cannabis research has revealed the complexities of the entourage effect.

Shelf stability has emerged as one of the biggest challenges. Like fresh produce, truffles degrade quickly if not kept under controlled conditions. For RLH, understanding how to preserve potency over time is key to developing future formulations, whether in pill or extraction form. “Consistency is always the goal when it comes to drug discovery,” Shapiro notes.

 

Strategic Growth Through M&A                                                                    Beyond consumer products and R&D, RLH is also exploring mergers and acquisitions as a path to scale. Shapiro says the focus is on acquiring brands with strong recognition and the potential to be cash flow positive, rather than companies burning capital. “A great Instagram account and loyal customers can be half the battle,” he notes. The idea is to consolidate products, share resources, and expand distribution while maintaining financial discipline.

Still, opportunities are scarce. After reviewing more than 40 companies over the past two years, Shapiro says nearly all were losing money. The demands of major retailers compound the challenge—fulfilling large orders requires significant upfront inventory and the ability to survive long payment cycles, which can stretch 90 days or more.

While RLH has heard of pioneering efforts, such as Oregon’s first psilocybin edibles, local ownership laws, and public company reporting requirements make direct entry into that market difficult. For now, the company continues to evaluate partnerships and acquisitions that align with its strategy, while supporting others that advance the industry. As Shapiro puts it, “Rising tides lift all boats.”

 

Looking Ahead                                                                                                        Red Light Holland is narrowing its focus on CPG products, leveraging its experience in the Netherlands while preparing for a global market. While the company continues some cultivation, its strategy centers on creating standardized, science-backed psilocybin products that can reach more people and address the growing mental health crisis. “We’re a psilocybin company at the end of the day,” says Shapiro, “focused on products that can help people, responsibly and sustainably, while navigating complex regulations and building a foundation for future growth.” By combining research, consumer insights, careful regulatory planning, and selective M&A, RLH is positioning itself to take psilocybin from niche wellness shops to mainstream markets worldwide.

Cannabusiness Sustainability

Taking Cannabis Global: Inside Somai Pharmaceuticals’ Multi-Country Strategy

No Comments

 

In an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and CEO of Somai Pharmaceuticals, has created a blueprint for scaling cannabis worldwide with pharmaceutical discipline and regulatory agility. With headquarters in Lisbon and operations in 12 countries today, Somai is preparing to reach 18 by year’s end.

The company has already secured distribution in Germany, the UK, Italy, Australia, and New Zealand, with France recently authorizing Somai’s products for its growing patient program. By the end of this year, six more markets, including parts of Eastern Europe, will be added to the roster.

 

“Every new country is like starting a company from scratch,” Sassano said in an interview. “You have to understand not only the national regulations but also how local medical communities perceive cannabis, how prescriptions are written, and what distributors are required to do. There’s no one-size-fits-all approach.”

 

Operating across borders has taught Somai how to adapt to widely different healthcare environments. In Germany, cannabis is covered by insurance in some instances, requiring negotiations with health funds. In the UK, the market is dominated by private clinics and cash-paying patients. Australia and New Zealand have highly structured import programs, while France is still moving cautiously through pilot projects.

This incremental, country-by-country buildout has given Somai real-world experience operating across multiple regulatory systems, positioning the company as one of the most credible voices on international cannabis harmonization.

 

High Standards Are Key

At the core of Somai’s global strategy is its pharmaceutical manufacturing facility in Lisbon, certified under EU-GMP (Good Manufacturing Practice). This certification is a mandatory requirement for selling medical-grade cannabis products in the EU and most international markets.

 

“EU-GMP is the gold standard,” Sassano says. “Without it, you simply can’t access the bulk of the world’s regulated medical markets.”

 

This distinction highlights one of the biggest differences between the US and international cannabis industries. In the United States, the market is fractured by a state-by-state model, with companies forced to duplicate infrastructure in every new state because products can’t cross state lines. By contrast, Somai can centralize manufacturing in Portugal and distribute to multiple countries. Products produced in Lisbon are eligible for export across Europe, Australia, New Zealand, South Africa, Brazil, and other compliant markets.

Unlike US operators who may quickly launch products like gummies with minimal oversight, a EU-GMP market-authorized medicine requires approximately two and a half years of validation, stability testing, and regulatory review before reaching patients. The payoff is consistency, safety, and the ability to meet the expectations of regulators, physicians, and patients alike.

By owning EU-GMP manufacturing and pairing it with distribution partnerships across 12 (soon 18) countries, Somai is among a select handful of cannabis companies capable of bringing pharmaceutical-grade products to the global market.

 

Strategic Partnerships, Cultivation, and Research

Somai’s global growth relies on a carefully balanced supply chain strategy that combines in-house cultivation with an extensive network of international partners. In addition to cultivating indoor flower at its own facilities, it also works with about 15 cultivation partners worldwide.

In most European markets, pharmaceutical cannabis must move through distributors before reaching pharmacies. Somai works with leading distribution companies, ensuring products reach doctors and patients in compliance with local laws.

Research partnerships are also part of Somai’s business strategy. The company collaborated with a university in Lisbon to conduct clinical research evaluating its manufacturing process, ensuring consistency from one product to another and from batch to batch. This validation of consistency is crucial for Somai to claim medical status and prove it.

“There are really only five global operator brands today in the market, and then a lot of localized brands, clinic brands, and white-label brands,” Sassano notes. “Our focus is on building a pharmaceutical brand with true international reach.”

 

Pharmaceutical Rigor from the Start

“In pharmaceuticals, quality is binary,” Sassano explains. “Either you meet the exacting standards or you don’t. There is no middle ground.”

This applies from raw material sourcing to batch release protocols. Unlike the US, which often requires independent third-party lab testing, the EU herbal medicine framework permits EU-GMP-certified facilities, such as Somai, to conduct all necessary testing in-house. Somai operates its own EU-GMP lab, a rarity in cannabis but standard in pharma.

The lab operates under strict oversight from a Qualified Person (QP), who leads the independent Quality Assurance (QA) department. The QA/QP team conducts regular onsite reviews of all procedures and documentation, ensuring that production, laboratory testing, and batch releases adhere to rigorous protocols. “Nobody can influence the lab or its reports,” Sassano emphasizes. Each product undergoes multiple checks: raw material testing, formulation verification, and random dosage confirmation.

Even packaging and labeling are treated with pharmaceutical precision. Labels must comply with each country’s language and dosage requirements, and patient information leaflets are tailored to the regulatory environment. “It might seem like a small thing, but one mistake on a label can stop a shipment at customs and delay patient access by months,” Sassano notes.

Sassano supports the rigorous framework. “Doctors will only prescribe, and patients will only trust cannabis if it meets the same standards as any other medicine on the shelf.”

 

Navigating a Patchwork of Regulations

Some nations allow doctors to prescribe freely, while others limit access to a narrow list of conditions. Even within the same country, patients may face dramatically different experiences.

Sassano points to Italy as a case in point. While prescriptions are permitted, the way pharmacists prepare medicines can vary region by region. “A patient in Milan might get a different preparation than a patient in Rome, even with the same prescription,” he explains. “That creates inconsistency for patients and makes it extremely challenging for producers to standardize.”

The difference between magisterial preparations and finished dosage form medicines illustrates the unevenness of the system. In newer markets, such as the UK and Australia, patients now receive finished dosage products that are fully packaged, labeled, and ready to use, just like any other pharmaceutical. But in older systems, pharmacists were often required to compound medicines themselves, a legacy from the early years when manufacturers didn’t exist and flower was the only product available.

Germany still clings to this model. Pharmacy compounding laws require pharmacists to fill vape cartridges or re-bottle oils instead of allowing manufacturers to deliver standardized, child-proof, finished dosage forms directly. “In some cases, they’re literally just swapping a cap, calling it magisterial prep, and charging patients double,”

Sassano notes. “It’s an archaic system that needs to go.”

Despite these hurdles, Sassano sees eventual harmonization as inevitable. “Europe cannot sustain a market where 27 countries have 27 different systems,” he argues. “Over time, patient demand and cross-border trade will push regulators toward standardization. Finished dosage forms are the future.”

 

Global Market Access

Somai’s EU-GMP certification positions it for international distribution. Unlike the US state-by-state system, where borders are closed and infrastructure must be duplicated in each market, EU-GMP allows a single production hub to supply multiple countries. As a recognized pharmaceutical standard, it enables Somai’s products to move across borders into any country that accepts EU-GMP medicines.

This flexibility is critical because cannabis is treated differently around the world. Europe and many international markets have strong herbal medicine traditions, so cannabis extracts fall under the herbal pharmacopoeia as true medicines and are subject to rigorous pharmaceutical rules. In contrast, the US market is closed off under FDA oversight, which historically favors synthetic cannabinoids over botanical extracts.

Still, Somai is positioning itself for future entry. “We’re working with the U.S. Department of Veterans Affairs because there is no federally approved cannabis extract made domestically,” Sassano says. “If cannabis is ever integrated into federal programs, it will need to be a registered medicine, not a dispensary product.”

Beyond the U.S., Somai has already secured FDA-style registrations in countries like Thailand, is pursuing approvals in Japan, and has entered France’s government-controlled medical program, where cannabis is subsidized for patients.

“These are true medicines that can travel cross-border,” Sassano says. “Wherever cannabis is accepted as a medicine, we want to be there.”

 

Conclusion

Michael Sassano’s insights offer a roadmap not just for his company but for the entire industry. “Cannabis is a medicine first,” he emphasizes. “Our responsibility is to show regulators, doctors, and patients that it can be produced, prescribed, and trusted like any other pharmaceutical. Once that trust is established, global acceptance will follow.”

Quick Q&A Recap

Q: Who is Michael Sassano?
A: Michael Sassano is the founder and CEO of Somai Pharmaceuticals, a company scaling cannabis globally with pharmaceutical-grade standards.

Q: What is Somai Pharmaceuticals’ global footprint?
A: Somai currently operates in 12 countries and plans to expand into 18 by the end of the year.

Q: Why is EU-GMP certification important in cannabis?
A: EU-GMP (Good Manufacturing Practice) is the gold standard for pharmaceutical products and a requirement to sell medical cannabis in most international markets.

Q: How does Somai’s model differ from U.S. cannabis companies?
A: Unlike U.S. operators confined by state borders, Somai can centralize manufacturing in Portugal and distribute across multiple countries under EU-GMP rules.

Q: What are the main challenges of international cannabis expansion?
A: Each country has unique regulations, healthcare systems, and distribution requirements, forcing companies to adapt market by market.

Q: How does Somai ensure pharmaceutical quality?
A: The company operates its own EU-GMP-certified lab with strict Quality Assurance oversight, ensuring consistency, safety, and regulatory compliance.

Q: What role do partnerships play in Somai’s strategy?
A: Somai balances in-house cultivation with about 15 global cultivation partners and works with leading distributors to reach doctors and patients.

Q: What is the future of cannabis regulation in Europe?
A: Sassano believes eventual harmonization is inevitable, with standardized finished dosage forms replacing outdated pharmacy compounding practices.

Q: Is Somai targeting the U.S. market?
A: Yes. Somai is collaborating with the U.S. Department of Veterans Affairs and preparing for potential federal approval of cannabis-based medicines.

The Shift Toward Stability Testing for Cannabis Products

By Liz Cornish
No Comments

Cannabis products are increasingly held to the same standards as food and pharmaceuticals, and that means verifying how their potency and composition change over time. Cannabis stability testing provides the data needed to establish reliable shelf life, confirm product consistency, and guide formulation optimization for improved stability and performance. 

Cannabinoids and terpenes are complex, naturally derived compounds that react to light, heat, oxygen, and humidity. Even slight variations in these factors can alter potency or flavor. By conducting cannabis shelf life studies, manufacturers can determine how long a product maintains its intended properties under defined storage conditions. 

Why Cannabis Stability Testing Is Necessary 

Unlike synthetic pharmaceuticals, cannabis-based formulations are highly sensitive to environmental conditions. During processing, exposure to air or high temperatures can cause degradation of cannabinoids and oxidation of terpenes. Packaging materials also play a role—improper barriers can accelerate loss of aroma and potency. 

To quantify these effects, samples are stored under controlled conditions such as: 

  • Long-term studies: 25°C ± 2°C / 60% RH ± 5% RH 
  • Accelerated studies: 40°C ± 2°C / 75% RH ± 5% RH 

Products are tested at specific intervals for changes in potency, moisture, and appearance. The results support expiration dating, regulatory compliance, and product reliability across batches. Over time, stability datasets also reveal how formulation or packaging changes affect performance, helping manufacturers continually refine production methods. 

Temperature and Storage: The Role of Cold Chain 

Temperature control directly affects cannabinoid and terpene integrity. Fluctuating conditions during storage or transport can cause emulsion separation, texture changes, or reduced potency. 

For high-value products, a cold supply chain helps maintain consistent quality. Refrigerated or temperature-monitored storage slows degradation, stabilizes emulsions, and preserves the sensory characteristics that distinguish premium formulations. 

Although cold chain infrastructure can be costly, it is becoming a defining factor in cannabis quality assurance as brands compete on consistency and shelf stability. Stability study data can guide cold chain validation—determining the temperature range at which a product remains within specification. Those findings also support labeling statements such as “store below 25°C” or “refrigerate after opening,” allowing producers to base handling instructions on verified evidence rather than assumptions. 

Terpene Testing and Product Stability 

Terpenes are among the most volatile compounds in cannabis and degrade faster than cannabinoids. Their loss can indicate declining freshness long before measurable changes in potency occur. 

Despite their importance, terpene data are often missing from Certificates of Analysis (COAs). The omission isn’t usually due to a lack of interest, but rather to the complexity and cost of additional testing. 

Adding Terpene Profiling to Cannabis Potency Testing 

Integrating terpene profiling into cannabis potency testing programs offers deeper insight into product quality, aroma stability, and freshness.
However, accurate analysis requires: 

  • Advanced analytical instrumentation such as GC-MS or GC-FID 
  • Specialized calibration standards for quantifying individual terpenes 
  • Consistent testing intervals to track degradation patterns 

Interpreting Terpene Stability Data 

Testing terpene levels at regular intervals—monthly for accelerated studies and quarterly for long-term studies—reveals how quickly compounds evaporate or oxidize. Changes in terpene ratios (for example, limonene relative to myrcene) can identify which compounds drive shifts in aroma or flavor and signal the onset of degradation. These findings inform packaging design, storage recommendations, and shelf-life targets across product lines. 

Toward Standardized Terpene Stability Metrics 

As analytical capabilities advance, terpene stability metrics are expected to become part of routine quality control. Standardized testing will promote transparency, consistency, and product differentiation as consumers become more discerning about formulation and freshness. 

Formulation Optimization and Shelf Life Extension 

Stability data often reveal opportunities for formulation optimization—adjusting the balance of active ingredients, excipients, or stabilizers to enhance product longevity. 

Factors influencing cannabis product stability include: 

  • Excipient selection: Emulsifiers, antioxidants, and carrier oils can affect degradation rates. 
  • Packaging materials: Glass, plastic, and multilayer films offer varying levels of protection from oxygen and light. 
  • Moisture control: Desiccants and humidity-resistant containers can prevent microbial growth. 

Refining formulations based on empirical data extends shelf life, minimizes waste, and supports consistent consumer experiences across product lines. Effective formulation optimization bridges product development and regulatory compliance by ensuring each new formulation undergoes verification before scaling for the market. 

Designing a Reliable Cannabis Stability Program 

Effective cannabis stability testing starts with asking the right questions: 

  • Which environmental factors most affect each formulation? 
  • How should sampling intervals be defined? 
  • What level of potency loss is acceptable for regulatory or label claims? 

A comprehensive program typically includes: 

  • Accelerated testing for early insight into degradation trends 
  • Long-term studies that confirm real-world performance 
  • Validated analytical methods, such as HPLC for cannabinoids and GC-MS for terpenes 
  • Robust documentation of storage conditions, results, and analytical methods 

Data trending across studies allows manufacturers to identify recurring patterns in potency loss or terpene volatility. Predictive models based on historical data can estimate shelf life for new formulations with similar matrices, reducing time-to-market. These programs should follow the guidelines in ICH Q1A(R2) and align with GMP and ISO/IEC 17025:2017 standards to ensure data integrity and reproducibility. 

Connecting Stability Testing to Product Safety 

As cannabinoids and terpenes degrade, they can form secondary compounds that alter efficacy or safety. Moisture fluctuations may also allow microbial growth, which presents additional health risks. 

For infused products, ingredients such as fats, sugars, or botanical extracts are subject to oxidation or spoilage. Monitoring these variables through stability testing enables producers to identify early signs of degradation and take preventive measures, thereby protecting consumers and supporting regulatory compliance. 

Long-term datasets also support post-market surveillance by providing reference points when investigating product complaints or performance discrepancies. This continuity between laboratory data and field results builds trust with regulators, retailers, and consumers alike. 

The Future of Cannabis Stability Testing 

The cannabis industry continues to evolve toward pharmaceutical-grade quality systems. Future advances in analytical equipment, automation, and data management will make cannabis stability testing faster and more precise. 

The integration of stability studies, terpene profiling, and environmental monitoring will provide a comprehensive understanding of product performance over time. Manufacturers that invest in scientific validation and continuous improvement will be best positioned to meet both regulatory demands and consumer expectations. 

 

The Industry Is Failing At Last Mile Cannabis Preservation

2 Comments

Multiple scientific studies and lab results have provided compelling evidence that terpenes and volatile metabolites in cannabis rapidly degrade when exposed to light, oxygen, heat, and time, and therefore, reduce the entourage effect that depends on a specific balance of cannabinoids and terpenes. Because of this, what the product label promises is not what the consumer is getting.

The clock starts ticking at harvest, where terpenes start degrading at a rapid rate if not handled and stored correctly. Evaporation, oxidation, or structural change can alter both the composition and balance of compounds.

 

Fragile Aromas, Fading Effects: The Science of Terpene Loss

Terpenes, the aromatic compounds responsible for cannabis’s distinctive scent and effects, are highly sensitive to environmental stress. Studies show that these same conditions also degrade cannabinoids like THC, which converts to the less potent CBN over time. A 2021 study in the Journal of Cannabis Research found that flower stored at higher temperatures lost both THC and terpene content, while a 2024 Scientific Reports study revealed that UV light can degrade THC and CBD within days.

Each terpene reacts differently to stress. The lighter ones, like pinene and myrcene, start to fade at even modestly warm temperatures. Mid-weight terpenes such as limonene (that bright citrus note) and linalool (the floral lavender scent) hold on a bit longer but still break down when air or light gets in. Even the heavier, more stable compounds—like caryophyllene and humulene—eventually oxidize when storage conditions are poor. As those delicate aromas disappear, so does much of what makes each strain unique, subtly changing the flavor, scent, and effects of the flower.

 

Beverages Under Attack

Cannabis-infused beverages are particularly susceptible to potency loss if not properly stored. One primary cause is oxidation, where THC degrades into cannabinol (CBN), a compound with significantly less psychoactive effect. This transformation can occur rapidly in beverages due to the increased surface area of emulsified droplets and the presence of oxygen in the liquid. For instance, a study by Vertosa demonstrated that exposure to light and oxygen can lead to a potency loss of up to 8 percent over 12 weeks in specific formulations.

Additionally, physical interactions between the beverage’s emulsion and packaging materials can exacerbate potency loss. Hydrophobic emulsion droplets may adhere to hydrophobic surfaces, such as the interior linings of aluminum cans, leading to a reduction in cannabinoid content over time. To mitigate these issues, it’s best to use antioxidant-rich formulations, select appropriate packaging materials, and maintain proper storage conditions to maintain the efficacy of cannabis-infused beverages.

This is why information on a certificate of analysis can differ dramatically from what a consumer ultimately experiences in the end product.

When product degradation occurs, your label no longer accurately represents the contents of the product, and now the consumer is not receiving what they were promised. The danger also here is in dosing; if THC turns into CBN and loses potency because of degradation, but the label says 10mg of THC, the customer will not have an accurate baseline for dosing.

Improper storage without temperature control can lead to microbes growing in your product, so moisture content and water activity will play a big role in sabotaging shelf stability.

 

Degradation in Concentrates and Formulated Products

Concentrates, vape oils, and infused products are also vulnerable, if not more so, to degradation. No matter the format, cannabinoids and terpenes are delicate molecules that break down under unfriendly environmental conditions. In fact, research shows that these environmental factors can change the very chemistry of the extract, reducing potency and altering the product’s intended effects.

According to SC Labs, which regularly tests and studies terpene stability, even “sealed” vape cartridges and concentrate jars can experience terpene evaporation and oxidation when exposed to warm or brightly lit environments. Over time, this not only dulls the aroma and flavor but can also create new by-products as terpenes and cannabinoids oxidize. Monoterpenes, the lighter, more volatile compounds that give cannabis its bright, complex aroma, are especially quick to disappear, while heavier sesquiterpenes linger longer but still degrade without proper storage.

A review by Broughton and colleagues (2023) on cannabinoid stability found that THC and CBD are highly unstable under poor conditions, and their breakdown accelerates in liquid or semi-liquid formats like vape oils and emulsions. Another study published in Chemical Research in Toxicology found that high temperatures used in dabbing or vaping can produce degradation by-products, including isoprene and benzene derivatives, especially when terpene concentrations are high. Even during extraction, terpene loss can occur; the transition from flower to concentrate often strips away the lighter aromatics, leaving a narrower and chemically altered profile.

All of this means that the degradation “clock” starts much earlier than most realize, beginning at harvest, accelerating through packaging and transport, and continuing on the dispensary shelf. Proper temperature control, opaque airtight containers, and low-oxygen environments are needed to maintain chemical integrity and preserve the original profile that the product label promises.

 

Packaging and Storage Impact: Terpene and THC Stability
Terpene and cannabinoid degradation in cannabis products is heavily influenced by packaging and storage conditions. The material and closure system of the packaging are critical for preservation. Semi-permeable plastics or non-airtight closures can allow water vapor and oxygen to penetrate, accelerating product degradation. Packaging specifications, such as water vapor and oxygen transmission rates, directly affect shelf life; cheaper options with higher transmission rates can drastically reduce product quality. Improper handling—leaving packages open, exposing them to heat, or subjecting them to light—can further degrade THC and terpenes, making all cannabis formats, from flower to edibles to concentrates, vulnerable to potency loss.

Retailers play an extremely important role in the preservation process. How cannabis is stored, moved, and displayed in the store can either protect or accelerate product degradation. One of the biggest offenders is the widely used deli-style showcase for selling cannabis flower, where buds are exposed to light and frequent handling, dramatically increasing the risk of terpene and THC loss. Even the most carefully cultivated and processed products can lose stability if retailers fail to maintain proper temperature, light protection, and airtight handling during storage, stocking, and transfer.

The bottom line: Protecting and preserving cannabis means keeping the supply chain cool, airtight, and out of the light, from processing all the way to the retail shelf, where it might impact the stability of your product and a consumer’s experience.

 

 

 

 

 

 

 

 

 

From The Lab

An Inside Look at Germany’s Cannabis Supply Chain With The Grünhorn Group

No Comments

On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for cannabis aside from home cultivation or membership in non-commercial private clubs, both still limited by incomplete regulations. Unlike the United States, where dispensaries are the backbone of cannabis sales, Germany maintains a more tightly regulated model: patients must secure a doctor’s prescription and fulfill it through a pharmacy.

The next stage, Pillar 2, is expected to introduce licensed retail outlets for adult-use sales, eliminating the requirement for prescriptions. However, with the Christian Democratic Party now in office and maintaining a strong stance against cannabis legalization, these plans face significant uncertainty. While advocates remain hopeful for progress, the CDU’s opposition could delay, restrict, or even reverse parts of the rollout, leaving the future of Germany’s adult-use market in question.

In the meantime, Germany is laying the groundwork for a national infrastructure rooted in its medical system, a stark contrast to the fragmented, state-by-state patchwork in the U.S. This centralized approach not only offers greater oversight and consistency but also positions Germany as a potential model for other European nations exploring reform.

At the center of this rapidly evolving landscape is the Grünhorn Group, one of the country’s most influential players. With an estimated 20 percent market share serving between 5–7 million patients in a nation of 84 million, Grünhorn has established a vertically integrated supply chain that spans importing biomass from global producers, EU-GMP-certified manufacturing, and robust distribution networks. Beyond production, the company operates Germany’s largest online pharmacy platform, giving patients access to products from multiple manufacturers. According to Matthias Fischer, Managing Director of Canymed, Grünhorn’s distribution partner, the group generated €33 million in revenue in 2024, provided medicine to approximately 60,000 patients, and engaged with nearly 6,000 prescribing physicians.

 

Prioritizing Data Collection for Medical Research                                                              For Grünhorn, data is at the core of both its medical mission and its business strategy. The company systematically collects patient feedback on the effects of its products—whether for sleep, anxiety, focus, or other conditions—to inform evidence-based product development. This feedback loop allows Grünhorn to collaborate closely with cultivation partners in designing strains that balance cannabinoids and terpenes to address specific therapeutic needs.

Beyond patient-level insights, Grünhorn is also investing heavily in analytical research. The company operates a gas chromatograph to precisely measure and map the cannabinoid and terpene composition of imported biomass, creating a detailed strain database. To date, Grünhorn has cataloged between 400 and 500 strains of interest, providing one of the most comprehensive genetic and chemical libraries in Germany’s cannabis sector.

“I think the future lies in predicting and knowing which cannabinoids will effectively address specific health indications,” says Fischer, underscoring the company’s long-term vision of turning raw data into targeted, science-driven therapies.

 

Germany is an Import Market

While Germany has licensed domestic cultivation, led by producers such as Tilray, Demecan, and Aurora, the country remains heavily dependent on imports. According to Fischer, the quality of German-grown cannabis has not yet reached the standards set by established cultivation markets in Canada, Portugal, Denmark, and Colombia. To maintain product consistency and meet patient expectations, Grünhorn partners with a Canadian grower, underscoring the ongoing importance of international supply in Germany’s cannabis ecosystem.

Economic factors also weigh heavily on domestic production. High energy costs make large-scale cultivation within Germany particularly challenging, pushing wholesale prices above those of imported flower. As a result, most of the market is supplied by international partners who can cultivate at scale more efficiently and deliver the product at a lower cost.

This reliance on global supply chains is not unique to Grünhorn.

Cantourage, one of Germany’s largest medical cannabis manufacturers, has built its strategy around imports, maintaining partnerships with 40 cultivators across 17 countries. Together, these dynamics reinforce Germany’s role as one of the world’s largest import-driven cannabis markets, even as it develops its own infrastructure.

 

Bottlenecks in the Pharmacy System

Germany’s pharmacy network, spanning both retail and online channels, remains the cornerstone of cannabis dispensing in the country. As patient demand surges, many traditional pharmacies have launched digital platforms to streamline order management. Grünhorn has leaned into this shift, expanding its online pharmacy delivery while forging partnerships with local pharmacists who see cannabis as a valuable revenue driver.

Yet the system is under strain. Because only licensed pharmacists can legally fulfill prescriptions, they often face capacity challenges. Compounding, bottling, labeling, and testing must still be performed manually, creating bottlenecks in day-to-day operations. To keep pace, some pharmacists pre-produce standardized products based on everyday patient needs, despite the model being designed for on-demand compounding. Recognizing these inefficiencies, Grünhorn is investing in custom machinery and software solutions to help pharmacists scale production without compromising compliance, while maintaining oversight of quality and safety.

Another hurdle is product consistency. With prescriptions filled at thousands of independent pharmacies, often by third-party providers, slight variations in formulation are inevitable. “It’s like having 6,000 different factories manufacturing your product,” Fischer explains. To address this, Grünhorn is working on standardized fulfillment models to align independent pharmacies with the quality benchmarks already set by its own online platform.

To further streamline the process, Grünhorn has integrated telemedicine into its supply chain. Patients can now connect directly with physicians, obtain prescriptions, and submit them seamlessly for fulfillment. This innovation helps address a recurring frustration: doctors inadvertently prescribing products that are out of stock, despite having access to inventory databases, ultimately reducing delays and ensuring patients remain on consistent treatment plans.

 

Partnerships and Opportunities                                                                                  Grünhorn’s pharmacy data reveals that 20-30 percent of products generate 80 percent of revenue, indicating a potential for future product consolidation, according to Fischer. For investors, this presents an opportunity to fund medical brands with proven track records that are poised for growth and expansion.

In addition to producing its wholesale product line, Grünhorn is well-positioned and equipped to assist other brands looking to enter the German marketplace and welcomes co-branded product partnerships. They forged a partnership with Somai Pharmaceuticals, based in Portugal, resulting in a two-year, €10 million manufacturing and distribution deal.

Fischer also believes AI will play a significant role in managing the industry in the future, suggesting an opportunity for those looking to enter the German market through technological innovation.

“The biggest challenge we must overcome in the next couple of years is to generate data and medical studies,” Fischer emphasizes. “We have many products with nice ideas, interested patients, and qualifying physicians, but we need more studies and proven evidence to present to new doctors and insurance companies, who are still challenging cannabinoid therapy and requesting data studies.”

For more insights into the German market, listen to an interview with Matthias Fischer on the Innovating Cannabis podcast.

 

Arizona Commands the Nation’s Highest Cannabis Business Valuations

By , Gordon K. Sattro
No Comments

Whether it’s a single retail license, a multi-site operation, or a vertically integrated enterprise, deals in Arizona are fetching top-tier premiums – often exceeding price points in larger, more mature markets like California.

So, what’s driving these sky-high valuations? More importantly, how can industry players take advantage? Let’s break it down.

Arizona: Where Cannabis Assets Command a Premium

Over the past 24 months, dozens of transactions have closed in Arizona by way of consolidation, ranging from single dispensary sales to multi-unit portfolio deals. The results have been record-setting: in some cases a standalone retail license has sold for over $10 million, a figure unheard of in many other states. Arizona’s cannabis assets are, in a word, premium and are routinely attracting bids that surpass those in traditionally dominant market.. Clearly, Arizona has become a market where cannabis assets command a serious premium.

Why is this desert market so hot? Below are five key factors fueling Arizona’s elevated valuations.

Five Key Factors Driving Arizona’s Sky-High Cannabis Valuations

  1. Limited License Structure: Arizona’s cannabis market operates under a tightly restrictive license cap, with only 169 dispensary licenses statewide. This built-in scarcity means any available license instantly becomes a coveted asset. With far fewer retail outlets than demand requires, sellers hold the leverage – and can command steep prices as a result.
  2. Dual Licensure (Medical + Recreational): Many Arizona licenses are dual-use, meaning one license allows both medical and adult-use sales. This doubles a dispensary’s potential customer base overnight. Dual licensure translates to higher revenue per store, as each licensed operator can serve all segments of the market. Buyers are willing to pay a premium for this versatility and expanded market share.
  3. Strategic Location and Growing Consumer Base: Arizona boasts one of the fastest-growing populations in the U.S., with major metros like Phoenix and Tucson expanding rapidly. The state also enjoys booming tourist traffic and steady streams of interstate shoppers (especially from nearby prohibition states such as Texas, Utah, and New Mexico). On top of that, Arizona offers a favorable business climate with relatively low taxes and fees, which further boosts profitability for operators. In short, demand is high and operating costs are relatively manageable which all results in a perfect recipe for rich valuations.
  4. Robust Sales and Profitability: Thanks to limited competition and dual-use sales, Arizona dispensaries tend to generate strong revenues and healthy profit margins. Each store services a large customer pool, often resulting in higher sales per dispensary than in states with more saturated markets. Buyers see that Arizona operations can yield a significant return on investment, which justifies paying top dollar for a foothold in the market.
  5. Strong Investor Demand: The buzz around Arizona has drawn in deep-pocketed buyers from across the country. Green Life has witnessed both institutional investors and high-net-worth individuals eagerly bidding for Arizona licenses and companies. This competitive buyer pool pushes valuations even higher – it’s not uncommon to see bidding wars drive a sale price well above the initial asking. When multiple buyers are vying to enter or expand in Arizona, sellers ultimately reap the reward in the form of lofty sale prices.

Navigating the Arizona Market: Buyers and Sellers

Buyers: How to Win in a Hot Market
 For buyers, Arizona’s high valuations mean you must come prepared. To successfully acquire an asset in this competitive market, buyers should:

  • Be ready to move quickly. Attractive opportunities often trigger bidding wars, so speed and decisiveness are essential once a viable deal hits the market.
  • Expect to pay a premium. Understand that Arizona assets are expensive for good reason – low-ball offers won’t win deals here. Savvy buyers budget for top-tier prices and focus on the long-term upside.
  • Leverage local expertise. Partnering with experienced cannabis brokers or advisors (like Green Life Business) who know the Arizona landscape can help you identify opportunities early and navigate the complex regulatory environment with confidence.

Sellers: How to Maximize Your Sale
 For sellers, Arizona’s moment in the spotlight presents a prime opportunity – but preparation is key to capturing maximum value. Green Life Business guides sellers through critical steps to capitalize on the market, including:

  • Packaging the business for maximum value. We help organize financials, compliance records, and growth stories into a compelling presentation that attracts top-tier buyers.
  • Securing pre-qualified buyers. Through an extensive network, we screen and line up buyers who have the interest and the funds, ensuring a smoother sale process.
  • Navigating regulatory hurdles. From state licensing rules to local regulations, our team helps sellers handle all compliance and license transfer requirements without derailment.
  • Closing quickly and transparently. We strive for deals that close on time, with no surprises, giving both parties confidence from offer to final handshake.

By taking these steps, sellers can tap into Arizona’s aggressive pricing environment and drive their deal to the finish line efficiently.

Bottom Line


Arizona isn’t just hot – it’s on fire. In a market where asset values elsewhere are cooling, Arizona continues to deliver record-setting valuations fueled by scarcity, strong demand, and proven profitability.

With experience selling High Times, Statehouse, and securing the largest all-cash cannabis transaction since 2022, Green Life Business has the expertise and track record to position your Arizona business for the strongest possible sale outcome. Whether you’re considering an exit, recapitalization, or expansion, our team brings the market knowledge and deal execution needed to maximize value.

Let’s talk. The next great Arizona transaction could be yours.

Greenlife Business Group Inc.

NECANN Atlantic City: Insights on NJ’s Emerging Market

By Pam Chmiel
No Comments

The excitement and interest around New Jersey are impossible to ignore because of its potential to be one of the most lucrative cannabis markets in the country. Since legalization, operators have been racing to open doors, capture consumers, and keep pace with evolving regulations, as they battle sky-high operating costs, shifting compliance rules, and the uncertainty of how consumer demand will shake out.

At NECANN’s Atlantic City conference, a panel of industry insiders gathered to offer their insights on where the Garden State’s market is heading. Moderated by Jacob Robbins of Longview Strategic, the panel brought together voices from the packaging, brewing, and manufacturing industries to explore the opportunities, roadblocks, and trends reshaping the industry.

“This market is young and growing fast,” Robbins said as he opened the session. “But it’s also unpredictable. Success requires both planning and adaptability.”

Lesson From Other States: Scaling Smart                                                                                    Jason Marshall of AE Global, a company specializing in packaging and supply chain solutions, began by pointing to lessons from more mature cannabis markets. Drawing on his background in consumer packaged goods (CPG) with companies like Pepsi and General Mills, Marshall stressed that packaging in cannabis is far more than just compliance.

“Packaging is the vehicle for trust and brand identity,” he said. “In a crowded dispensary, that’s how you stand out.”

The data shows just how crowded New Jersey has become. In 2023, the state tracked 2,100 SKUs; this year, that number more than doubled to 4,800. For consumers, that means unprecedented choice. For businesses, it means competing for shelf space and consumer attention in ways that look increasingly like mainstream retail.

Marshall’s advice was clear: treat cannabis like any other consumer market. Strategic planning is essential, but rigid strategies rarely succeed. Operators must be nimble and prepared to adjust pricing, packaging, and distribution to reflect changing consumer behavior and evolving regulatory requirements. “The playbook is always shifting,” Marshall said. “The winners are the ones who can shift with it.”

Regulations vs. Market Reality                                                                                                           If packaging is where brands differentiate, regulation is where they stumble. Chuck Garrity, founder of Death of the Fox Brewing Co., knows firsthand what happens when rules lag behind business. His experience navigating New Jersey’s craft beer rollout gave him a sobering perspective on what to expect when he entered the cannabis industry with his dispensary, Frosted Nug.

“We saw the same messy process with craft beer,” Garrity said. “Government always lags behind business. Cannabis is no different.”

According to Garrity, the problem isn’t just bureaucracy; it’s who writes the rules. Lobbyists, he argued, play an outsized role in shaping legislation. Unless operators engage lawmakers directly, they risk being boxed out of decisions that will shape their businesses for decades.

“Operators need relationships with mayors, senators, and regulators. If you’re not at the table, you’re on the menu,” he warned.

The threat of overregulation is real. Rules that are too restrictive, he said, could choke off innovation and slow down the momentum New Jersey needs to stay competitive with neighboring states. For Garrity, political advocacy is not optional; it’s survival.

Manufacturing, Innovation, and White Labeling                                                      Where Garrity sees a risk in policy, Hursh Patel sees opportunity in production. Patel, founder of Red Oak Cannabis, detailed his company’s investment in a CGMP-certified manufacturing facility powered by AI-driven automation to raise the bar on quality, consistency, and efficiency.

“Automation and quality control are everything in cannabis manufacturing,” Patel said. Consumers expect consistency. Retailers demand it. AI helps us deliver it at scale.”

But Patel’s bigger play is in white-labeling. In a landscape where every dispensary is trying to carve out its identity, exclusive brands offer a way to build loyalty and improve margins.

“White label gives retailers the chance to control more of the value chain,” Patel explained. “It’s a high-margin growth path, but it only works with the right partners and strict quality standards.”

The strategy has been successful in other states, where dispensaries have developed in-house brands that compete directly with national players. In a crowded New Jersey market, Patel argued, it could mean the difference between profitability and mediocrity.

Beverages: The Next Super-Category                                                          One trend drew universal attention: beverages. While still a small slice of the market, cannabis drinks are gaining momentum across the U.S., and panelists believe New Jersey won’t be far behind.

Marshall pointed to the West Coast, where dispensaries in California and Oregon are increasingly “fridge-heavy,” dedicating prime space to cannabis beverages. Branding is more experiential, with products designed to appeal to wellness-minded and socially conscious consumers who might never consider smoking a joint.

“Beverages are shaping up to be a super-category,” Marshall said. “In three to five years, they could be the preferred consumption method.”

National brands like Cycling Frog are already building mainstream awareness, helping normalize the idea of drinking cannabis instead of alcohol. For New Jersey operators, beverages represent both an opportunity and a challenge: they require cold storage, different packaging standards, and consumer education. But if the predictions hold true, they could also be the next major driver of growth for dispensaries.

Roadblocks On The Horizon                                                                         Despite the optimism, delivery remains an obstacle, being both costly and underdeveloped. Insurance premiums are steep, and regulations create more friction than efficiency. Without reform, consumers may continue to rely on traditional purchasing channels.

Interstate commerce also looms large. While federal legalization remains stalled, most agree that it’s a matter of when, not if. For New Jersey, with its high operating costs, the threat is real. Once interstate trade opens, local producers may struggle to compete with lower-cost operators on the West Coast.

Then there’s politics. New Jersey’s upcoming gubernatorial election could have a major impact on the regulatory climate. A shift in leadership could accelerate reform or stall it indefinitely.

Key Takeaways for New Jersey Operators                                                  By the end of the session, a handful of themes emerged as survival strategies for cannabis businesses in the Garden State:

  1. Build flexibility into strategy. The rules and market conditions will change—your business model must be ready to adapt.
  2. Study other state markets. Learn from the missteps and successes of other states.
  3. Cultivate political relationships. Lobbying power isn’t optional; it’s how laws get written.
  4. Explore white-label opportunities. House brands can expand margins and consumer loyalty.
  5. Prepare for beverages. There seems to be a big white space for beverages. Whether it’s in two years or five, drinks are poised to lead consumer adoption.

A Market Still Taking Shape                                                                         The challenges are significant, and the future is uncertain, just like any other maturing cannabis market. But for operators willing to stay lean, resourceful, invest in relationships, and think creatively about products, the opportunity remains immense.

“This is still the early innings,” Robbins said in closing. “The operators who thrive will be the ones who treat this like the serious, dynamic consumer market it is, while never forgetting that in cannabis, everything can change overnight.”

 

What you will learn:

  • What makes New Jersey one of the most promising cannabis markets in the U.S.?

  • How are operators adapting to high operating costs and changing regulations?

  • What lessons can New Jersey learn from more mature cannabis markets?

  • Why is packaging important for brand identity and consumer trust in cannabis?

  • How can white-label products help dispensaries improve margins and loyalty?

  • Why are cannabis beverages considered a potential “super-category” for growth?

  • What regulatory and political challenges could impact New Jersey operators?

  • How can operators stay flexible and thrive in a rapidly evolving cannabis market?

Turning Crisis Into Opportunity- Navigating Cannabis Receivership Successfully

By , Gordon K. Sattro
No Comments

The age of cannabis receiverships is here. If you’re a creditor, operator, landlord, or investor in a troubled cannabis business, you have a choice: watch value evaporate, or step up and run a disciplined, court-supervised sale that maximizes recoveries and preserves the company as a going concern. Because federal prohibition blocks access to bankruptcy courts (cannabis companies can’t file Chapter 11 like other businesses), state-court receivership has become the go-to process for plant-touching companies to orderly market and sell assets under a receiver’s oversight.

Importantly, receivership doesn’t have to mean rock-bottom pricing. In cannabis especially,  where licenses are scarce and operations are fragile, real value is preserved or lost based on execution. From my experience, great outcomes come from controlling key variables, reducing buyer risk, and spotlighting a path to upside even in distress.

 

Green Life Business Group: Setting the Market in Cannabis Receiverships                                 At Green Life Business Group, we’ve been at the center of several high-visibility cannabis receiverships nationwide. Our team has designed competitive sale processes, driven bidder engagement, and closed transactions under court confirmation; often setting the market for what distressed cannabis assets can fetch. A few examples:

  • High Times / Hightimes Holding Corp.: We handled the receivership sale of the iconic High Times portfolio, marketing everything from the flagship West Hollywood dispensary to valuable IP like the domain 420.com. The process reportedly generated 36 offers in just 17 days, and ultimately the High Times magazine and Cannabis Cup brands were bought out of bankruptcy for $3.5 million. (The premium web domain 420.com alone attracted six-figure bids, underscoring the demand we tapped into.
  • StateHouse Holdings (Harborside / Urbn Leaf / Loudpack): In late 2024, we brokered what may be the largest cannabis receivership sale in U.S. history – the StateHouse Holdings asset portfolio. This statewide collection of 11 retail stores (Harborside and Urbn Leaf brands), plus cultivation, nursery, and processing facilities, boasted over $120 million in combined annual sales. Under our management, the court-supervised bidding (ending Jan 15, 2025) drew strong interest and set a new benchmark for distressed deals at this scale.
  • Element 7 (Multi-Site Retail & Licenses): In mid-2025, we ran an innovative Zoom auction for Element 7’s California portfolio – five retail/license sites located in Marina, Rio Dell, South San Francisco, Oakland, and Firebaugh. This court-ordered receivership sale was widely marketed with a June 30 bid deadline. By conducting the auction via Zoom (with upfront bidder deposits and pre-approved procedures), we maximized participation from qualified buyers across the state.
  • Canndescent: Our track record extends to distressed cultivation assets as well. We facilitated the sale of a 67,000 sq. ft. cannabis cultivation facility (part of Canndescent’s holdings) through receivership, highlighting that even large-scale grows can find eager buyers when packaged and presented correctly. This demonstrated our ability to execute receivership transactions not just in retail and brands, but also in high-value cultivation operations.

 

What Actually Maximizes Value in a Cannabis Receivership?                                                  Whether you’re a receiver, secured creditor, board member, or potential buyer, focusing on the following levers can mean the difference between a mediocre outcome and a great one:

Sell it as a going concern whenever possible: Keep the business operating (and in good standing) throughout the sale process. Retain key staff and continue serving customers if feasible. Buyers will pay a premium for continuity i.e., active licenses, sellable inventory, and revenue still flowing. Even if operations must pause, maintain all licenses in good standing and have a clear, budgeted plan to restart. The goal is to present an ongoing business, not a shuttered one, at auction.

  • Design a competitive process and prove it in court: Don’t run a secret or sloppy sale. Set up a structured, transparent bidding process and be prepared to show the judge you left no value on the table. This means establishing a secure data room with a universal NDA and requiring proof-of-funds from all interested parties. Launch a national marketing campaign to reach strategic and financial buyers (not just local operators). Publish a clear timeline (launch date, Q&A cutoff, bid deadline, auction date, court hearing) so everyone knows the rules. Whenever appropriate, use a stalking-horse bidder to set a floor price,  with reasonable overbid increments and a modest breakup fee that encourages challengers rather than deterring them. Finally, get the court to bless simple, defensible bid procedures up front. By the time you’re in court for approval, you can demonstrate a competitive, fair process that maximized value.
  • Package assets the way buyers underwrite: Present the business in the same way a buyer will evaluate it. That means providing the data that matters for each asset type. For retail dispensaries, highlight the license status, lease terms (and assignability), store performance (revenue, customer traffic, normalized margins), any local taxes or fees, and valuable assets like POS data or loyalty program stats. For cultivation or processing facilities, detail the canopy size and production capacity, yields and cost of goods by SKU, the state of environmental controls (HVAC, lighting, etc.), genetics or IP included, harvest schedules, and any offtake or tolling contracts in place. For brands and intellectual property, provide clarity on trademark ownership (classes and territories covered), domain names and social media handles, historical revenue attributable to the brand, and assurance of clean title (no hidden liens or infringement issues). In short, package each component as a turnkey opportunity with clear upside, so buyers can easily underwrite value without uncertainty.
  • De-risk the close ahead of the auction: One of the biggest value-killers is a winning bid that falls through due to transfer issues. Proactively remove as many closing uncertainties as possible before the auction. For example, work with landlords early to secure estoppel certificates and consent to assignment of leases; have those assignment documents ready in the data room. Coordinate with regulators ahead of time on change-of-ownership approvals or any required M&A filings – and set realistic timelines for transfer so bidders know what to expect. Map out any tax obligations, successor liability questions, or UCC lien releases that could affect the sale, and clearly communicate which liabilities a buyer will assume (or avoid). By delivering a near “plug-and-play” deal to the highest bidder, you increase bidder confidence and the price they’re willing to pay.
  • Tell a growth story buyers can model: Buyers pay up when they see a credible path to ROI. Offer a concise investment memo or executive summary that outlines the growth opportunity post-sale. This might include market comparables, the store’s customer demographics and trade area, any expansion or optimization projects in the pipeline, and even a 13-week cash flow forecast to bridge the business through the closing period. Show how the buyer can step in and quickly ramp revenue or profitability. When bidders can easily model the upside, they are more likely to bid aggressively rather than low-ball for perceived risk.

 

Why Receiverships Are Surging (and What It Means for Pricing)                                               The recent surge in cannabis receiverships is no coincidence. Legal operators are struggling under crippling tax burdens and fierce illicit-market competition, which squeeze margins and cash flow. In some cases, companies are also saddled with heavy debts or legal liabilities from ambitious mergers and expansions that didn’t pan out (for example, Gold Flora’s 2023 merger left it absorbing a partner’s $575 million burn rate). All these pressures have pushed more operators into court-monitored sales as a last resort to repay creditors.

The good news is that a well-run receivership process can still attract capable buyers and command respectable valuations – even in today’s stressed market. By removing liens and uncertainties, keeping the licenses alive, and running a competitive auction, distressed cannabis assets don’t have to sell for pennies on the dollar. With multiple bidders and a clear path to operation, receivership sales can approach fair market value rather than true “fire sale” prices. In short, even though the circumstances are distressed, the outcome doesn’t have to be, if you execute the process correctly.

 

Why Buyers Pursue Receivership Assets                                                                                          For savvy buyers, receivership sales can be rare opportunities to acquire licensed cannabis assets at significant discounts compared to traditional M&A deals. Distressed sales often reflect temporary hardships rather than long-term potential, allowing well-capitalized purchasers to swoop in at a fraction of the cost of building or buying similar assets in a healthy market. Moreover, because these transactions are court-supervised to protect creditors, the assets are typically sold “free and clear” of liens and encumbrances, giving buyers clean title and minimal legacy risk.

These court-approved auctions enable buyers to unlock hard-to-secure assets – retail licenses in limited markets, fully built-out cultivation facilities, established brands with loyal followings – that would be otherwise difficult or costly to obtain. And since many receivership sales keep the business running through closing (with licenses, staff, and customers still in place), the buyer can step directly into an operating enterprise on Day One. Essentially, you’re acquiring a functioning cannabis business at a distressed valuation, with immediate cash flow upside once you stabilize and optimize under new ownership. For those positioned to move quickly, it’s an attractive way to expand into new markets or verticals at a bargain price.

 

Bottom Line                                                                                                                              Receiverships don’t have to be fire sales. With the right brokered process, transparent bid rules, and pre-cleared closing paths, everyone wins: the court gets certainty, creditors get fair recoveries, buyers capture real upside, and the industry keeps valuable assets as going concerns rather than seeing them fall apart. That’s how you truly maximize value in a cannabis receivership.

 

What You Will Learn:

  • What is a cannabis receivership and why is it becoming more common?
  • How does federal prohibition impact bankruptcy options for cannabis businesses?
  • Why is state-court receivership the preferred process for distressed cannabis companies?
  • How can a disciplined receivership sale preserve value in a struggling cannabis business?
  • What factors determine whether a cannabis receivership sale fetches a strong price?
  • How did the High Times receivership demonstrate demand for cannabis IP and brand assets?
  • What made the StateHouse Holdings receivership one of the largest in U.S. history?
  • How did Element 7 use a Zoom auction to maximize bidder participation?
  • Can large-scale cannabis cultivation facilities, like Canndescent, successfully sell through receivership?
  • What steps should receivers take to design a competitive and court-approvable sale process?
  • How should cannabis assets be packaged to match buyer underwriting expectations?
  • Why is de-risking the closing process critical to maximizing sale value?
  • How can a well-run receivership sale prevent assets from selling for “fire sale” prices?
  • Why are receivership assets attractive to buyers compared to traditional M&A opportunities?

 

 

Making the Cannabis Industry SAFER for America

By Melissa Kuipers Blake, Osiris Morel
No Comments

After nearly a decade of conversation and education on the Hill, the Senate Banking, Housing and Urban Affairs Committee finally held a markup on the Secure and Fair Regulation (SAFER) Banking Act. Previously known as the SAFE Banking Act, the “R” was included to account for Sen. Jack Reed’s (D-RI) concerns with Section 10. The senator shared his concerns publicly on May 11 during the “Examining Cannabis Banking Challenges of Small Businesses and Workers” hearing. Sen. Reed said that Section 10’s language “would make it more difficult for federal regulators to raise the alarm about relationships with any customer that presents significant risks to the bank” and shared that such a provision is “not limited to the marijuana industry or the cannabis industry,” but that it “could allow pyramid schemes or all sorts of other interesting activity to go on without an effective response by the regulator.” Since then, he and a group of bipartisan members, including Majority Leader Chuck Schumer (D-NY), Senate Banking Committee Chair Sherrod Brown (D-OH), and Sens. Steve Daines (R-MT), Cynthia Lummis (R-WY), Kevin Cramer (R-ND) and Kyrsten Sinema (I-AZ), have worked endlessly to develop language to resolve such concerns while maintaining GOP support, leading to the SAFER Banking Act.

Number of Depository Institutions Actively Banking
Cannabis-Related Businesses in the United States
(Reported in SARS)

The difference between the SAFE Banking Act and the SAFER Banking Act can mainly be found in Section 10. Changes focus on and determines:

  • How regulators terminate bank accounts;
  • How the Federal Deposit Insurance Corporation (FDIC) develops guidance for financial institutions serving state-licensed cannabis businesses;
  • How income derived from state-legal cannabis business activity is managed;
  • That personal and political beliefs cannot impact a financial regulator’s decision making;
  • That federal banking regulators and state banking supervisors and their secretaries of Commerce and Treasury would create rules to increase access to deposit accounts and how such individuals would enhance customer relationships with rural, low- and moderate-income, unbanked and tribal communities; and
  • How the FDIC would conduct a biennial survey and report on barriers for small- and medium-sized businesses.

During the markup on Wednesday, members introduced and discussed a range of amendments related to criminal justice reform, the racial wealth gap, federal regulators and their processes, rescheduling and the opioid epidemic. In total, there were six amendments, one by Chairman Brown, as well as Sens. Mike Crapo (R-ID), Bill Hagerty (R-TN), Mike Rounds (R-SD) and two by Sen. Raphael Warnock (D-GA). Sen. Brown’s amendment, which would make technical changes to the bill, was the only amendment to prevail on a 17-6 vote.

Senate Majority Leader Chuck Schumer (center), Senate Finance Committee Chair Ron Wyden (right) and Senator Cory Booker (left)

To begin the markup, Chair Brown said that propelling this legislation is a critical step in reversing the damage done by the war on drugs and clarified that the SAFER Banking Act would create a better financial system for small and medium-sized cannabis businesses that lack access to such traditional banking services. Sen. Daines, who served as the committee ranking member in place of Sen. Tim Scott (R-SC), who was in California preparing for the Republican presidential debate, shared that although he opposes legalization or decriminalization, he agreed to sponsor and support the SAFER Banking Act because it would fix the current banking system for cannabis businesses nationwide. After hearing remarks from Sens. Lummis, Catherine Cortez Masto (D-NV) and Sinema, the committee voted on the bill, and approved its passage to the Senate floor on a 14-9 vote. Senators voting in favor of the bill were Brown, Tester, Warren, Reed, Menendez (by proxy), Smith (by proxy), Warner, Fetterman, Cortez-Masto, Sinema, Van Hollen, Lummis, Cramer and Daines, and voting against the measure were Sens. Warnock, Scott (by proxy), Crapo, Tillis, Kennedy, Haggerty, Vance and Britt.

After the vote, Sen. Jeff Merkley (D-OR) thanked Sen. Rand Paul (R-KY) and former Republican Sen. Cory Gardner (CO) for their early efforts and for bringing the legislation and issue to the chamber’s attention and concluded that he hopes to have a robust discussion with the full Senate chamber.

With the bill out of committee, it heads to the Senate floor for additional input, discussion and potentially a vote. Majority Leader Schumer has said he intends to bring the SAFER Banking Act to the floor “with all due speed” and noted that he is committed to attaching Rep. Dave Joyce’s (R-OH) Harnessing Opportunities by Pursuing Expungement (HOPE) Act and Rep. Brian Mast’s (R-FL) Gun Rights and Marijuana (GRAM) Act to the final legislation. Sen. Schumer also shared that such provisions would address the war on drugs, bolster social equity and criminal justice reform and protect Second Amendment rights for medical cannabis patients.

When the SAFER Banking Act will receive floor time remains unclear, but Leader Schumer has made numerous representations that he would like to see it done this year.

Sustainability in Cannabis Packaging: Balancing Preservation and Environmental Impact

By Jack Grover
2 Comments

Even a cursory review of cannabis reveals that the market has been notoriously wasteful, polluting the environment with chemical fertilizers, misused pesticides, contaminated plants, and—perhaps most problematically—thoughtlessly excessive packaging.

The industry is in dire need of sustainable practices, and the easiest way to start an impactful new trend is from the outside in: a.k.a., adjusting how you’re parceling your products.

Honing in on sustainable packaging isn’t just a good move for the environment. It’s also more cost-effective, less labor-intensive and allows you to provide consumers with the best possible version of your flower—no matter how far through the supply chain it’s had to travel before hitting retail shelves.

Cannabis has progressed: It’s time for its packaging to do the same

By the time legalization began sweeping the nation, the industry already had several decades of experience operating underground. With that discretion came a lot of built-in habits around not attracting attention, and for packaging, the focus was solely on not looking like a cannabis product.

An overabundance of plastic isn’t cutting it anymore—not only when it comes to environmental friendliness, but for the integrity of the product itself.

Today, increased legalization grants operators the freedom to expand without the fear of being seen, and as a result, there’s no longer any excuse for wasteful packaging to be the industry’s norm. Glass jars, Ziplocks and an overabundance of plastic isn’t cutting it anymore—not only when it comes to environmental friendliness, but for the integrity of the product itself.

“I’ve been designing packaging in the cannabis industry since 2013, and a lot of trends have come and gone. We used to put flower in plastic Rx jars and paper envelopes. In general, there was a lot of waste: excess boxes and jars that all get thrown away,” says Legacy’s Chief Cannabis Officer Ryan Hedrick. “And when consumers pull the products out of those containers, your marketing doesn’t remain intact. The box gets thrown away, and now they’re just carrying around a labelless jar. Not only is it bad for the environment, but it isn’t helping you promote your brand at all.”

How sustainable storage optimizes curing and shelf life of flower

As for the curing process, Hedrick used to use airtight buckets, which both took up a lot of room and wasn’t at all effective for maintaining cannabis’s ideal humidity levels. He’s since switched to passive atmospheric packaging, which utilizes increasingly popular technology to keep humidity—and sustainability—in mind. “The buckets weren’t letting any moisture out. On top of that, you can imagine how much room 165 five-gallon buckets takes up in a grow space,” Hedrick says.

The same goes for long-term storage. With humidity-controlled bags, operators can rest assured that their product will maintain its efficacy, because as soon as that pack is sealed, the humidity level is guaranteed to stay the same.

Cannabis brand Lava Leaf Organics relies on passive atmospheric packaging for efficient storage—mainly because of the reduction in carbon footprint and increase in terpene preservation.

“When we think about the energy involved in packaging and shipping large amounts of heavy glass jars compared to TerpLoc bags, it was an easy decision for us,” said Lava Leaf Organics CEO Tony Martinez.

“The bags are recyclable, and compared to glass jars with child-resistant lids, they’re much better at preserving terpenes. Using sustainable packaging allows us to put our best foot forward and to better control our customer’s brand experience.”

Tips for making sustainable storage work for you

Sustainable storage is an environmentally-responsible move for the cannabis industry to make, but when weighing the pros and cons of a big switch like this, operators should also keep in mind how positively it will impact their end product, consumer’s experience, and, subsequently, their industry-wide reputation.

Some product packaging examples in the market today

Placing your products in eco-friendly bags is just the start. There are definitely more tips and tricks operators can take advantage of to prolong the use of sustainable materials and ensure they’re leaving as small a footprint as possible. For example, Hedrick’s team reuses their passive atmospheric packaging for maximum efficiency—especially when it comes to bulk storage or curing.

“We mark all of our storage bags with the original strain, so we can reuse that bag for the same strain as long as it passes testing along the way. When I do so, I take a mixture of SaniDate and water to make sure everything is sanitized and clean,” Hedrick said. “That allows me to reuse them for about 3-4 months’ worth of curing and storage. You can reuse a bucket in that same way, but when it’s time to replace it, you’re still spending another $15-$17.”

Sustainable, humidity-controlled packaging is also ideal for testing consistency. If you send in five buckets of the same strain to be tested, you run the risk of them all sitting at wildly different humidity levels, which means some might pass, and others might be rendered trash.

All of the environmental benefits aside, using sustainable packaging just makes cents—literally. “Essentially, I’m saving a minimum of half a million in packaging every year. That’s my entire staff’s salary for two months. That’s incredible, impactful, significant savings that can make a huge difference for a business trying to expand.”